ADCP Bioassay Effector Cell FcγRIIa (H variant)-NFAT/Jurkat
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. FcγRIIa is the predominant Fcγ receptor involved in the ADCP process. FcγRIIa is expressed in myeloid effector cells, including macrophages and neutrophils, where it plays a role in the activation of these effector cells. Several clinical studies have studied the correlation of a FcγRIIa polymorphism (R131H) and the response to IgG1 subclass monoclonal antibodies (mAbs) such as rituximab. Engineered amino-acid substitutions in Fc-mAbs have been developed to enhance the mAb-mediated phagocytosis of tumor cells by macrophages.
Recombinant Jurkat T cell expressing a firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Histidine variant.
|Expressed gene:||FcγRIIa (H variant)-NFAT|
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Freeze Medium:||90% FBS+10% DMSO|
|Culture Medium:||RPMI-1640+10%FBS+1ug/ml puromycin+400ug/ml hygromycin|
|Storage:||Immediately upon receipt, store in liquid nitrogen.|
|Application(s):||Characterize the Fc effector function of antibodies.|
|IV. Description of Host Cell Line|
|Disease:||Childhood T acute lymphoblastic leukemia|
|Ⅴ. Representative Data|
Figure 1. Dose response of Rituximab in ADCP Bioassay Effector Cell FcyRlla (H variant) /NFAT Reporter-Jurkat (C2)，the EC50 was 21.5ng/ml.